PharmaEngine (ROCO:4162) ROCE %: 13.72% (As of Dec. 2025)


ROCO:4162 PharmaEngine Inc ROCO:4162
79 GF Score
Price NT$57.90
GF Value NT$114.87
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is PharmaEngine ROCE %?

PharmaEngine ROCO:4162 -1.86% 79 ROCE % is 13.72% as of Dec. 2025. GuruFocus rates ROCO:4162 with a GF Score™ of 79/100 and a GF Value™ of NT$114.87 (Significantly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PharmaEngine's annualized ROCE % for the quarter that ended in Dec. 2025 was 13.72%.

PharmaEngine  (ROCO:4162) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PharmaEngine ROCE % Related Terms

PharmaEngine ROCE % Historical Data

* Premium members only.

The historical data trend for PharmaEngine's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaEngine ROCE % Chart

PharmaEngine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.71 10.03 8.72 46.65 9.83

PharmaEngine Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 151.01 9.38 3.43 14.44 13.72
ROCO:4162
79GF Score
PharmaEngine Inc ROCO:4162
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaEngine ROCE % Calculation

PharmaEngine's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=509.432/( ( (5847.811 - 443.053) + (5147.512 - 187.146) )/ 2 )
=509.432/( (5404.758+4960.366)/ 2 )
=509.432/5182.562
=9.83 %

PharmaEngine's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=669.432/( ( (4907.683 - 112.333) + (5147.512 - 187.146) )/ 2 )
=669.432/( ( 4795.35 + 4960.366 )/ 2 )
=669.432/4877.858
=13.72 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 13.72% mean?
PharmaEngine (ROCO:4162) has a ROCE % of 13.72% as of Dec. 2025.
Is PharmaEngine's ROCE % too high?
PharmaEngine's current ROCE % is 13.72%. Overall, PharmaEngine has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's ROCE % compare to VRTX and REGN?
PharmaEngine's ROCE % of 13.72% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. PharmaEngine's current ROCE % is 13.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$114.87, compared to a current price of NT$57.90 — trading 49.6% below its estimated fair value. The current ROCE % is 13.72%. PharmaEngine's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current ROCE % is 13.72% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmaEngine (ROCO:4162) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued. The current stock price of NT$57.90 is trading 49.6% below its estimated GF Value™ of NT$114.87. GuruFocus considers PharmaEngine to be Significantly Undervalued.

Key valuation signals for ROCO:4162:

  • ROCE %: 13.72%
  • GF Value™: NT$114.87 vs. price of NT$57.90 (49.6% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmaEngine Business Description

Address No. 10, Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
79GF Score

Get the complete analysis for ROCO:4162

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$57.90
Price
NT$114.87
GF Value